Serum cystatin C: A non-invasive marker of liver fibrosis or of current liver fibrogenesis in chronic hepatitis C?

Annals of Hepatology

Volumn 11, Issue 5, 2012, Pages 648-651

  Ladero, José M ^a   Cárdenas, María C ^b   Ortega, Luis ^b   González Pino, Andrea ^b   Cuenca, Francisca ^b   Morales, César ^b   Lee Brunner, Anna ^b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Chronic hepatitis C; Cystatin C.; Hepatitis C virus; Liver fibrosis

Indexed keywords

CYSTATIN C;

ADULT; AGED; ARTICLE; CHRONIC LIVER DISEASE; DISEASE CLASSIFICATION; DISEASE MARKER; FEMALE; FIBROGENESIS; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY FUNCTION; LABORATORY TEST; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; METAVIR SCORE; PORTAL HYPERTENSION; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SCORING SYSTEM; STAGING;

EID: 84865331845     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31437-1     Document Type: Article

References (16)

1. Kleiner DE. The liver biopsy in chronic hepatitis C: a view from the other side of the microscope. Semin Liver Dis 2005; 5: 52-64.
2. Gressner AM, Gao CF, Gressner OA. Non-invasive biomar-kers for monitoring the fibrogenic process in liver: A short survey. World J Gastroenterol 2009; 15: 2433-2440.
3. Ladero JM. Noninvasive evaluation of liver fibrosis in patients with chronic hepatitis C. Hepat Mon 2011; 11: 698-700.
4. Randers E, Erlandsen EJ. Serum cystatin C as an endogenous marker of the renal function-a review. Clin Chem Lab Med 1999; 37: 389-395.
5. Francoz C, Glotz D, Moreau R, Durand F. The evaluation of renal function and disease in patients with cirrhosis. J Hepatol 2010; 52: 605-613.
6. Gerbes AL, Gülberg V, Bilzer M, Vogeser M. Evaluation of serum cystatin C concentration as a marker of renal function in patients with cirrhosis of the liver. Gut 2002; 50: 106-110.
7. Cholongitas E, Shusang V, Marelli L, Nair D, Thomas M, Patch D, Burns A, et al. Review article: renal function assessment in cirrhosis-difficulties and alternative measurements. Aliment Pharmacol Ther 2007; 26: 969-978.
8. Takeuchi M, Fukuda Y, Nakano I, Katano Y, Hayakawa T. Elevation of serum cystatin C concentrations in patients with chronic liver disease. Eur J Gastroenterol Hepatol 2001; 13: 951-955.
9. Chu S-C, Wang C-P, Chang Y-H, Hsieh YS, Yang SF, Su JM, Yang CC, et al. Increased cystatin C serum concentrations in patients with hepatic deisease of various severities. Clin Chim Acta 2004; 341: 133-138.
10. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994; 20: 15-20.
11. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526.
12. Friedman SL. Mechanisms of hepatic fibrogenesis. Gas-troenterology 2008; 134: 1655-1669.
13. Shi GP, Sukhova GK, Grubb A, Ducharme A, Rhode LH, Lee RT, Ridker PM, et al. Cystatin C deficiency in human atherosclerosis and aortic aneurisms. J Clin Invest 1999; 104: 1191-1197.
14. Gressner AM, Lahme B, Meurer SK, Gressner O, Weiskir-chen R. Variable expression of cystatin C in cultured trans-differentiating rat hepatic stellate cells. World J Gastroenterol 2006; 12: 731-738.
15. Neuman MG, Benhamou JP, Marcellin P, Valla D, Malkiewicz IM, Katz GG, Trepo C, et al. Cytokine-chemokine and apoptotic signatures in patients with hepatitis C. Transl Res 2007; 149: 126-136.
16. Seo YS, Jung ES, An H, Kim JH, Jung YK, Kim JH, Yim HJ, et al. Serum cystatin C level is a good prognostic marker in patients with cirrhotic ascites and normal serum creatini-ne levels. Liver Int 2009; 29: 1521-1527.